CurrentCignaPolicy IP0320

Imbruvica for Non-Oncology Uses

Cigna drug coverage policy defining prior authorization and medical necessity criteria for Imbruvica when used for non-oncology indications, with explicit FDA-approved chronic graft-versus-host disease criteria and exclusion of other non-oncology uses.

Policy Summary

PayerCigna

PolicyImbruvica for Non-Oncology Uses

Policy CodePolicy IP0320

Change TypeRevised; Added

Effective DateSep 1, 2025

Next Review Date

Key ActionPrior Authorization is required for benefit coverage of Imbruvica; document that the patient has tried at least one systemic medication for graft-versus-host disease to meet medical necessity.

SourceLink

POLICY UPDATE CHANGES

Updated conventional systemic treatment criteria from 'inadequate response..unless contraindicated or intolerant' to 'tried'.

Updated title from 'Ibrutinib for Non-Oncology Uses' to 'Imbruvica for Non-Oncology Uses'.

Added Rezurock (belumosudil), Niktimvo (axatilimab-csfr), hydroxychloroquine, rituximab, pentostatin, interleukin-2, cyclosporine, tacrolimus, sirolimus, and an etanercept product to examples of systemic medications.

1Covered Non-Oncology Indications (per policy)

All othersNon-oncology uses considered not medically necessary

1 yearApproval Duration for cGVHD when criteria met

Coverage Summary

Cigna's drug coverage policy (Policy Number IP0320, effective 2025-09-01, last reviewed 2025-09-01) addresses Imbruvica (ibrutinib) when used for non-oncology indications. The policy defines prior authorization and medical necessity criteria, explicitly aligning coverage with the FDA-approved chronic graft-versus-host disease (cGVHD) indication and relevant guideline recommendations. Imbruvica is covered for cGVHD when the policy criteria are met; other non-oncology uses are considered not medically necessary.

Key Policy Facts

Policy IdentifierIP0320

Effective Date2025-09-01

Last Review2025-09-01

Approval Duration for cGVHD1 year (approve if criteria met)

Coverage StanceMixed — FDA‑approved for chronic graft‑versus‑host disease; other non‑oncology uses not medically necessary

Medical Necessity — Initial Therapy

Medical Necessity — FDA-Approved Indication: Chronic Graft-Versus-Host Disease (cGVHD)

Approve for 1 year if the patient meets BOTH of the following (A and B):

ALL of the following

A: Patient is ≥ 1 year of age
B: Patient has tried at least one systemic medication for graft-versus-host disease
Examples of systemic medications include: corticosteroids (methylprednisolone, prednisone), imatinib, low-dose methotrexate, sirolimus, mycophenolate mofetil, Jakafi (ruxolitinib tablets), Rezurock (belumosudil tablets), Niktimvo (axatilimab-csfr intravenous infusion), hydroxychloroquine, rituximab, pentostatin, interleukin-2 (e.g., Proleukin [aldesleukin intravenous infusion]), cyclosporine, tacrolimus, sirolimus, an etanercept product.

Continuation / Duration

When the cGVHD criteria are met, Imbruvica approvals are provided for a duration of 1 year. Prior authorization is required and all approvals are issued for the duration noted in the policy.

Not Medically Necessary / Exclusions

Not Medically Necessary

Imbruvica for any other non-oncology use is considered not medically necessary.

ANY of the following

Any non-oncology indication other than chronic graft-versus-host disease as defined above

Applicable Codes

Policy Identifiermixed

IP0320

Coverage Policy Number

Provider Actions & Billing

Prior Authorization

Prior authorization required

Prior Authorization is required for benefit coverage of Imbruvica. Approvals are provided for the duration noted (e.g., 1 year for chronic graft-versus-host disease when criteria are met).

Documentation Required

Documentation of prior systemic therapy

Provider must document that the patient has tried at least one systemic medication for graft-versus-host disease to meet medical necessity. Examples of systemic medications listed in the policy include: corticosteroids (methylprednisolone, prednisone), imatinib, low-dose methotrexate, sirolimus, mycophenolate mofetil, Jakafi (ruxolitinib tablets), Rezurock (belumosudil tablets), Niktimvo (axatilimab-csfr intravenous infusion), hydroxychloroquine, rituximab, pentostatin, interleukin-2 (e.g., Proleukin [aldesleukin intravenous infusion]), cyclosporine, tacrolimus, sirolimus, and an etanercept product.

Clinical Evidence & References

Evidence cited includes the FDA Prescribing Information for Imbruvica (tablets, capsules, and oral solution – December 2024) and multiple NCCN guideline versions (2024–2025) referenced for B-cell lymphomas, CNS cancers, CLL/SLL, graft-versus-host disease, Waldenström macroglobulinemia, and related indications. The policy background states it aligns coverage with the FDA-approved cGVHD indication and NCCN guideline recommendations.

Background

Imbruvica (ibrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor with multiple oncology indications (for example, CLL/SLL, mantle cell lymphoma, and Waldenström macroglobulinemia). This policy specifically addresses non-oncology uses by aligning coverage with the FDA-approved indication for chronic graft-versus-host disease and incorporating guideline recommendations into medical necessity criteria.

Definition — Systemic medication for graft-versus-host disease: medications listed as examples in the policy, including corticosteroids (methylprednisolone, prednisone), imatinib, low-dose methotrexate, sirolimus, mycophenolate mofetil, ruxolitinib (Jakafi), belumosudil (Rezurock), axatilimab-csfr (Niktimvo), hydroxychloroquine, rituximab, pentostatin, interleukin-2 (e.g., Proleukin), cyclosporine, tacrolimus, sirolimus, and etanercept products.

Revision History

9/15/2024revised

Reworded conventional systemic treatment criteria from 'inadequate response..unless contraindicated or intolerant' to 'tried' (changed phrasing to require the patient has tried at least one systemic medication).

9/15/2024revised

Administrative title change: updated policy title from 'Ibrutinib for Non-Oncology Uses' to 'Imbruvica for Non-Oncology Uses'.

9/1/2025addedLatest

Expanded illustrative list of prior systemic therapies that satisfy the 'tried at least one systemic medication' requirement by adding Rezurock (belumosudil), Niktimvo (axatilimab-csfr), hydroxychloroquine, rituximab, pentostatin, interleukin-2 (e.g., Proleukin/aldesleukin), cyclosporine, tacrolimus, sirolimus, and an etanercept product (examples included in Note under graft-versus-host disease criteria).